Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 4/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.40 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.40 |
| ▸ | GRIK1 | P39086 | 4/20 | 0.39 |
| ▸ | GRIK2 | Q13002 | 4/20 | 0.39 |
| ▸ | GSR | P00390 | 2/20 | 0.39 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.39 |
| ▸ | GRM8 | O00222 | 1/20 | 0.39 |
| ▸ | GRM6 | O15303 | 1/20 | 0.39 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.39 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.39 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL191236 | 1.00 | NOS3 (0.41) | NOS3NOS1NOS2ALDH1A1SLC1A2 | |
| SCHEMBL191235 | 1.00 | NOS3 (0.41) | NOS3NOS1NOS2ALDH1A1SLC1A2 | |
| SCHEMBL28580283 | 0.90 | GSR (0.43) | NOS3NOS1NOS2ALDH1A1GSR | |
| SCHEMBL13639864 | 0.84 | SLC1A1 (0.55) | SLC1A2SLC1A1SLC1A3GRIK1GRIK2 | |
| SCHEMBL19699429 | 0.83 | IDO1 (0.34) | SLC1A1 | |
| SCHEMBL1067509 | 0.83 | IDO1 (0.34) | SLC1A1 | |
| SCHEMBL1067514 | 0.83 | IDO1 (0.34) | SLC1A1 | |
| SCHEMBL30980082 | 0.83 | IDO1 (0.34) | SLC1A1 | |
| SCHEMBL10314812 | 0.81 | NOS3 (0.38) | NOS3NOS1NOS2ALDH1A1SLC1A2 | |
| SCHEMBL20591675 | 0.81 | NOS3 (0.38) | NOS3NOS1NOS2ALDH1A1SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11332485-B2 | Penicillin-binding protein inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2022-05-17 | — | — | US | disclosed |
| US-20200157123-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-05-21 | — | — | US | disclosed |
| CN-110959008-A | Penicillin binding protein inhibitors | 维纳拓尔斯制药公司 | 2020-04-03 | — | — | CN | disclosed |
| US-8106091-B2 | Inhibitors of IKK-beta serine-threonine protein kinase | CHROMA THERAPEUTICS LTD. (GB) | 2012-01-31 | — | — | US | disclosed |
| US-8106091-B2 | Inhibitors of IKK-beta serine-threonine protein kinase | CHROMA THERAPEUTICS LTD. (GB) | 2012-01-31 | — | — | US | disclosed |
| EP-2086956-B1 | INHIBITORS OF IKK- BETA SERINE-THREONINE PROTEIN KINASE | CHROMA THERAPEUTICS LTD (GB) | 2011-09-14 | — | — | EP | disclosed |
| US-20100069473-A1 | Inhibitors Of IKK-Beta Serine-Threonine Protein Kinase | CHROMA THERAPEUTICS LTD. (GB) | 2010-03-18 | — | — | US | disclosed |
| EP-2086956-A1 | INHIBITORS OF IKK- BETA SERINE-THREONINE PROTEIN KINASE | Chroma Therapeutics Limited (GB) | 2009-08-12 | — | — | EP | disclosed |
| WO-2008053185-A1 | INHIBITORS OF IKK-β SERINE-THREONINE PROTEIN KINASE | CHROMA THERAPEUTICS LTD. (GB) | 2008-05-08 | — | — | WO | disclosed |
| US-5326760-A | Aminobutanoic acid compounds having metalloprotease inhibiting properties | GLAXO, INC. (US) | 1994-07-05 | — | — | US | disclosed |
| WO-1994000119-A1 | AMINOBUTANOIC ACID COMPOUNDS HAVING METALLOPROTEASE INHIBITING PROPERTIES | GLAXO INC. (US) | 1994-01-06 | — | — | WO | disclosed |
| US-5252560-A | Cyclic imide derivatives, compositions and use | GLAXO INC. (US) | 1993-10-12 | — | — | US | disclosed |
| EP-0520573-A1 | Cyclic imide derivatives | GLAXO INC. (US) | 1992-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157123-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | PEPD, BPGM, EBPL | NOS3 4668/4885NOS1 4500/4885NOS2 4597/4885 |
| US-20100069473-A1 | Inhibitors Of IKK-Beta Serine-Threonine Protein Kinase | IKBKB, IKBKE, CHUK | NOS3 150/4885NOS1 296/4885NOS2 611/4885 |
| US-11332485-B2 | Penicillin-binding protein inhibitors | PEPD, BPGM, EBPL | NOS3 4668/4885NOS1 4500/4885NOS2 4597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.